Wall Street Numbers logo
Wall Street Numbers logo
Wall Street Numbers
NewAmsterdam Pharma Company N.V. company logo
NewAmsterdam Pharma Company N.V. logo

NewAmsterdam Pharma Company N.V. (NAMS)

Profile

Company profile for NewAmsterdam Pharma Company N.V. (NAMS)
MetricValue
Full NameNewAmsterdam Pharma Company N.V.
TickerNASDAQ: NAMS
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CountryNetherlands
IPO
IndexesNot included
Websitenewamsterdampharma.com
Employees77

Key Metrics

NewAmsterdam Pharma Company N.V. Key Details
MetricDateValue
Price$35.45
Price, 1D Change+4.20%
Market Cap$4B
-
PE Ratio-
Beta0.89
Revenue$46M
Revenue, 1Y Change+223.37%
EPS-$2.56
EPS, 1Y Change-18.89%

Chart

Add series to chart(max: 6)
Series
SUGGESTED SERIES
NewAmsterdam Pharma Company N.V. chart

Events

NewAmsterdam Pharma Company N.V. Events
MetricDateValue
Next Earnings
Last Qtr. Earnings
Last Ann. Earnings
Last Ex-DividendN/AN/A
Next Ex-DividendN/AN/A
Last SplitN/AN/A
Next SplitN/AN/A
Last Ticker ChangeN/AN/A
Next Ticker ChangeN/AN/A

🔒 Log In To Unlock Full Data

Estimates

NAMS Estimates
MetricDateValue
EPS-$2.56
EPS Estimate-$1.34
EPS Est. Change+47.75%
Revenue$45.56M
Revenue Estimate$23.44M
Revenue Est. Change-48.55%
Current Price$35.45
Price Target-$46.02
Price Tgt. Change-+29.82%

🔒 Log In To Unlock Full Data

EPS

NAMS EPS reported versus estimate values
YearEstimateReportedSurprise / Exp.
-$2.24-$2.15+3.86%
-$1.98-$2.56-29.02%
-$1.34N/A+47.75%
-$1.50N/A+41.27%
NAMS EPS reported versus estimate values chart

Revenue

NAMS revenue reported versus estimate values chart
YearEstimateReportedSurprise / Exp.
$14.24M$14.09M-1.05%
$31.13M$45.56M+46.35%
$23.44MN/A-48.55%
$35.22MN/A-22.69%
NAMS revenue reported versus estimate values chart

🔒 Log In To Unlock Full Data

Performance

NAMS Performance
MetricDateValue
Price, 1Y+36.14%
Price, 3Y+199.31%
Market Cap, 1Y+42.85%
Market Cap, 3Y+316.12%
Revenue, 1Y+223.37%
Revenue, 3Y+100.00%
EPS, 1Y-18.89%
EPS, 3Y-1,187.68%

🔒 Log In To Unlock Full Data

Technical Indicators

NAMS Technical Indicators
MetricDateValue
Current Price$35.45
SMA 200$26.33
SMA 200 vs Price-25.71%
SMA 50$36.79
SMA 50 vs Price+3.78%
Beta0.89
ATR$1.73
14-Day RSI49.58
10-Day Volatility37.30%
1-Year Volatility57.48%

Dividends

NAMS Dividends
MetricDateValue
N/A-
UpcomingN/AN/A
-
-
Dividends Paid$0.00
Payout Ratio0.00%

🔒 Log In To Unlock Full Data

Income & Profitability

NAMS Income & Profitability
MetricDateValue
Revenue$45.56M
EPS-$2.56
Gross Profit$45.45M
Gross Margin99.75%
Operating Profit-$176.29M
Operating Margin-386.91%
Net Income-$241.60M
Net Margin-530.25%
EBITDA-$241.49M

🔒 Log In To Unlock Full Data

Financial Health

NAMS Financial Health
MetricDateValue
Debt To Equity0.00
Current Ratio8.08
Quick Ratio8.08
Interest Coverage-
F-Score3
Altman Z-Score21.79

Valuations

NAMS Valuations
MetricDateValue
PE Ratio-
PS Ratio114.06
PB Ratio5.52
EV/EBITDA-16.36
Enterprise ValueN/A-

Balance Sheet

NAMS Balance Sheet
MetricDateValue
Book Value$757.50M
Cash & Equivalents$771.74M
Total Assets$864.62M
Current Assets$863.41M
Total Liabilities$107.12M
Current Liabilities$106.92M
Total Debt$448.00K
Short Term Debt$246.00K
Accounts Payable$4.74M

Expenses

NAMS Expenses
MetricDateValue
Total Expenses$221.85M
Operating Expenses$221.85M
Cost Of Goods Sold$113.00K
SG&A$70.45M
D&A$113.00K
Interest Expense$0.00
Income Tax-$1,000.00

Cash Flow

NAMS Cash Flow
MetricDateValue
CFO-$158.56M
CFI-$62.85M
CFF$659.51M
Capex$672.00K
Free Cash Flow-$159.24M

Recent analyst updates

NAMS Recent analyst updates
MetricDateValue
Stifel→
Goldman Sachs→
RBC Capital→
Needham→
Citigroup→
Wells Fargo
RBC Capital→
Goldman Sachs
Citigroup
Needham→

Analyst sentiment

Sentiment over the past month
NAMS analyst sentiment distribution chart

Institutional ownership

Largest institutional holders by ownership percentage
NAMS institutional ownership distribution chart

Screeners with NAMS

Data Sources & References

  1. NAMS Official Website www.newamsterdampharma.com
  2. Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1936258/000119312525265796/0001193125-25-265796-index.htm
  3. Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1936258/000095017025027339/0000950170-25-027339-index.htm
  4. NAMS Profile on Yahoo Finance finance.yahoo.com/quote/NAMS
  5. NAMS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/nams

FAQ

  • What is the ticker symbol for NewAmsterdam Pharma Company N.V.?

    The ticker symbol for NewAmsterdam Pharma Company N.V. is NASDAQ:NAMS

  • Does NewAmsterdam Pharma Company N.V. pay dividends?

    No, NewAmsterdam Pharma Company N.V. does not pay dividends

  • What sector is NewAmsterdam Pharma Company N.V. in?

    NewAmsterdam Pharma Company N.V. is in the Healthcare sector

  • What industry is NewAmsterdam Pharma Company N.V. in?

    NewAmsterdam Pharma Company N.V. is in the Biotechnology industry

  • What country is NewAmsterdam Pharma Company N.V. based in?

    NewAmsterdam Pharma Company N.V. is headquartered in Netherlands

  • When did NewAmsterdam Pharma Company N.V. go public?

    NewAmsterdam Pharma Company N.V. initial public offering (IPO) was on February 9, 2021

  • Is NewAmsterdam Pharma Company N.V. in the S&P 500?

    No, NewAmsterdam Pharma Company N.V. is not included in the S&P 500 index

  • Is NewAmsterdam Pharma Company N.V. in the NASDAQ 100?

    No, NewAmsterdam Pharma Company N.V. is not included in the NASDAQ 100 index

  • Is NewAmsterdam Pharma Company N.V. in the Dow Jones?

    No, NewAmsterdam Pharma Company N.V. is not included in the Dow Jones index

  • When was NewAmsterdam Pharma Company N.V. last earnings report?

    NewAmsterdam Pharma Company N.V.'s most recent earnings report was on November 5, 2025

  • When does NewAmsterdam Pharma Company N.V. report earnings?

    The next expected earnings date for NewAmsterdam Pharma Company N.V. is February 25, 2026